Immunological response against SARS-CoV-2 following full-dose administration of Comirnaty® COVID-19 vaccine in nursing home residents
Copyright © 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved..
OBJECTIVES: The current study was aimed at examining SARS-CoV-2 immune responses following two doses of Comirnaty® COVID-19 vaccine among elderly people in nursing homes.
METHODS: A prospective cohort study in a representative sample from nursing homes in Valencia (n = 881; males: 271, females 610; median age, 86 years) recruited residents using a random one-stage cluster sampling approach. A lateral flow immunochromatography device (LFIC) (OnSite COVID-19 IgG/IgM Rapid Test; CTK BIOTECH, Poway, CA, USA) was used as the front-line test for detecting SARS-CoV-2-Spike (S)-specific antibodies in whole blood obtained using a fingerstick. Residents returning negative LFIC results underwent venipuncture and testing for presence of SARS-CoV-2-S-reactive antibodies and T cells using the Roche Elecsys® Anti-SARS-CoV-2 S (Roche Diagnostics, Pleasanton, CA, USA), the LIAISON® SARS-CoV-2 TrimericS IgG assay (Diasorin S.p.A, Saluggia, Italy) and by flow cytometry, respectively.
RESULTS: The SARS-CoV-2-S antibody detection rate in nursing home residents was 99.6% (283/284) and 98.3% (587/597) for SARS-CoV-2 recovered and naïve residents, respectively, within a median of 99 days (range 17-125 days) after full vaccination. Three out of five residents lacking SARS-CoV-2-S antibodies had detectable S-reactive CD8+ and/or CD4+ T cells. In addition, 50/50 and 40/50 participants with detectable SARS-CoV-2 antibodies also had SARS-CoV-2-S-reactive interferon-γ-producing CD4+ and CD8+ T cells, respectively.
DISCUSSION: The Comirnaty® COVID-19 vaccine is highly immunogenic in nursing home residents.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases - 28(2022), 2 vom: 03. Feb., Seite 279-284 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Albert, Eliseo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 31.01.2022 Date Revised 07.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cmi.2021.09.031 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331604051 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331604051 | ||
| 003 | DE-627 | ||
| 005 | 20231225213828.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cmi.2021.09.031 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1105.xml |
| 035 | |a (DE-627)NLM331604051 | ||
| 035 | |a (NLM)34619398 | ||
| 035 | |a (PII)S1198-743X(21)00560-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Albert, Eliseo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunological response against SARS-CoV-2 following full-dose administration of Comirnaty® COVID-19 vaccine in nursing home residents |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.01.2022 | ||
| 500 | |a Date Revised 07.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a OBJECTIVES: The current study was aimed at examining SARS-CoV-2 immune responses following two doses of Comirnaty® COVID-19 vaccine among elderly people in nursing homes | ||
| 520 | |a METHODS: A prospective cohort study in a representative sample from nursing homes in Valencia (n = 881; males: 271, females 610; median age, 86 years) recruited residents using a random one-stage cluster sampling approach. A lateral flow immunochromatography device (LFIC) (OnSite COVID-19 IgG/IgM Rapid Test; CTK BIOTECH, Poway, CA, USA) was used as the front-line test for detecting SARS-CoV-2-Spike (S)-specific antibodies in whole blood obtained using a fingerstick. Residents returning negative LFIC results underwent venipuncture and testing for presence of SARS-CoV-2-S-reactive antibodies and T cells using the Roche Elecsys® Anti-SARS-CoV-2 S (Roche Diagnostics, Pleasanton, CA, USA), the LIAISON® SARS-CoV-2 TrimericS IgG assay (Diasorin S.p.A, Saluggia, Italy) and by flow cytometry, respectively | ||
| 520 | |a RESULTS: The SARS-CoV-2-S antibody detection rate in nursing home residents was 99.6% (283/284) and 98.3% (587/597) for SARS-CoV-2 recovered and naïve residents, respectively, within a median of 99 days (range 17-125 days) after full vaccination. Three out of five residents lacking SARS-CoV-2-S antibodies had detectable S-reactive CD8+ and/or CD4+ T cells. In addition, 50/50 and 40/50 participants with detectable SARS-CoV-2 antibodies also had SARS-CoV-2-S-reactive interferon-γ-producing CD4+ and CD8+ T cells, respectively | ||
| 520 | |a DISCUSSION: The Comirnaty® COVID-19 vaccine is highly immunogenic in nursing home residents | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Comirnaty®COVID-19 vaccine | |
| 650 | 4 | |a Nursing home residents | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a SARS-CoV-2-S antibodies | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Burgos, Javier S |e verfasserin |4 aut | |
| 700 | 1 | |a Peiró, Salvador |e verfasserin |4 aut | |
| 700 | 1 | |a Salas, Dolores |e verfasserin |4 aut | |
| 700 | 1 | |a Vanaclocha, Hermelinda |e verfasserin |4 aut | |
| 700 | 1 | |a Giménez, Estela |e verfasserin |4 aut | |
| 700 | 1 | |a Limón, Ramón |e verfasserin |4 aut | |
| 700 | 1 | |a Alcaraz, María Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez-Payá, José |e verfasserin |4 aut | |
| 700 | 1 | |a Díez-Domingo, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Navarro, David |e verfasserin |4 aut | |
| 700 | 0 | |a Valencian Vaccine Research Programme (ProVaVac) Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Burgos, J S |e investigator |4 oth | |
| 700 | 1 | |a Meneu de Guillerna, R |e investigator |4 oth | |
| 700 | 1 | |a Vanaclocha Luna, H |e investigator |4 oth | |
| 700 | 1 | |a Burks, D J |e investigator |4 oth | |
| 700 | 1 | |a Cervantes, A |e investigator |4 oth | |
| 700 | 1 | |a Comas, I |e investigator |4 oth | |
| 700 | 1 | |a Díez-Domingo, J |e investigator |4 oth | |
| 700 | 1 | |a Peiro, S |e investigator |4 oth | |
| 700 | 1 | |a González-Candelas, F |e investigator |4 oth | |
| 700 | 1 | |a Ferrer Albiach, C |e investigator |4 oth | |
| 700 | 1 | |a Hernández-Aguado, I |e investigator |4 oth | |
| 700 | 1 | |a Oliver Ramírez, N |e investigator |4 oth | |
| 700 | 1 | |a Sánchez-Payá, J |e investigator |4 oth | |
| 700 | 1 | |a Vento Torres, M |e investigator |4 oth | |
| 700 | 1 | |a Zapater Latorre, E |e investigator |4 oth | |
| 700 | 1 | |a Navarro, D |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases |d 1995 |g 28(2022), 2 vom: 03. Feb., Seite 279-284 |w (DE-627)NLM094580014 |x 1469-0691 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2022 |g number:2 |g day:03 |g month:02 |g pages:279-284 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cmi.2021.09.031 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2022 |e 2 |b 03 |c 02 |h 279-284 | ||